Back
Cardiff Oncology, Inc. 10K Form
Sell
35
CRDF
Cardiff Oncology, Inc.
Last Price:
$2.12
Seasonality Move:
11.94%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive CRDF News And Ratings
See the #1 stock for the next 7 days that we like better than CRDF
CRDF Financial Statistics
Sales & Book Value
| Annual Sales: | $683K |
|---|---|
| Cash Flow: | $-10.9M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $0.73 |
| Price / Book: | 2.91 |
Profitability
| EPS (TTM): | -0.79360 |
|---|---|
| Net Income (TTM): | $-50.4M |
| Gross Margin: | $279K |
| Return on Equity: | -81.17% |
| Return on Assets: | -65.58% |
Cardiff Oncology, Inc. Earnings Forecast
Key Cardiff Oncology, Inc. Financial Ratios
-
The Gross Profit Margin over the past 14 years for CRDF is 40.85%.
-
The Selling, General & Administrative Expenses for CRDF have been equal to 1,827.53% of Gross Profit Margin.
-
The Research & Development expenses have been 5,395.61% of Revenue.
-
The Net Earning history of CRDF is -6,651.68% of Total Revenues.
-
Per Share Earnings over the last 15 years have been positive in 7 years.
Cardiff Oncology, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | CRDF |
| CUSIP: | 14147L |
| Website: | cardiffoncology.com |
Debt
| Debt-to-Equity Ratio: | 0.02 |
|---|---|
| Current Ratio: | 4.2 |
| Quick Ratio: | 4.14 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
CRDF Technical Analysis vs Fundamental Analysis
Sell
35
Cardiff Oncology, Inc. (CRDF)
is a Sell
Is Cardiff Oncology, Inc. a Buy or a Sell?
-
Cardiff Oncology, Inc. stock is rated a SellThe current Cardiff Oncology, Inc. [CRDF] share price is $2.11. The Score for CRDF is 35, which is 30% below its historic median score of 50, and infers higher risk than normal.